[ad_1] Safety and mortality results in the Intrepid trial at one-year The study evaluated 33 patients enrolled in the early feasibility trial, focusing on safety and mortality outcomes. Zahr reported…
Tag: Structural Heart Disease
Surgeons warn it is too early to recommend a TAVR-first strategy for low-risk patients
[ad_1] One key takeaway from the STS/EACTS statement is that, using the same inclusion criteria found in the PARTNER 3 and Evolut Low Risk trials, SAVR is already associated with…
TAVR or SAVR? Where things stand now, from a surgeon’s perspective
[ad_1] While the 5-year results of the PARTNER 3 Low-Risk trial and the 4-year results from the Evolut Low-Risk trial both showed excellent results for TAVR, Grubb said the real…
TAVR and LAAO at the same time? Samir Kapadia breaks down the WATCH-TAVR trial
[ad_1] Details of the WATCH-TAVR trial The WATCH-TAVR trial’s primary endpoint was a composite of all-cause mortality, stroke, and major/life-threatening bleeding over a two-year period. Results of the trial revealed…
TAVR patients with cancer face higher risks of hospital readmission, serious bleeding
[ad_1] More than 6% of all patients presenting for TAVR had active cancer. TAVR patients with active cancer were less likely to present with hypertension, diabetes, obesity, coronary artery disease…
TAVR triumphs over surgery: Exploring 4-year data from the Evolut Low Risk trial
[ad_1] Steven Yakubov, MD, director of the MidWest Cardiology Research Foundation at OhioHealth Riverside Methodist Hospital, looked at overall valve performance for this study. This included structural valve deterioration, non-structural…
Edwards gains CE mark approval for new tricuspid valve replacement device
[ad_1] Edwards has been evaluating the safety and effectiveness of the Evoque system for quite some time. In November 2022, the company shared one-year data from the TRISCEND study that…
Haemonetics to acquire medical device company known for its TAVR guidewires for $253M
[ad_1] In addition, Haemonetics believes its commercial and clinical capabilities will increase patient access to OpSens devices and potentially help those devices gain regulatory approvals for new indications. “With the…
Cardiologists, cardiac surgeons push insurance company to rethink billing policy
[ad_1] Cardiologists, cardiac surgeons push insurance company to rethink … Cardiovascular Business [ad_2] Source link
What new tricuspid valve data tell us about the future of patient care
[ad_1] The biggest tricuspid study presented at ESC Congress 2023 was TRI-SCORE, which evaluated a tricuspid risk scoring system to determine the best time to intervene on patients. It also…